We confirmed the specificity of the signal by injecting the non-fluorescent PARP1-targeted drug Olaparib before administration of PARPi-FL, which resulted in a reduction of the fluorescent signal of the tumor by 60% (average radiant efficiency PARPi-FL: 2.4 × 108 versus Olaparib/PARPi-FL: 0.98 × 108, P < 0.001, Fig. 3c). The gene discussed is PARP1; the disease is neoplasm.